References
- Brook MS, Wilkinson DJ, Atherton PJ. Nutrient modulation in the management of disease-induced muscle wasting. Curr Opin Clin Nutr Metab Care. [Internet] 2017 [cited 2018 Jun 30];20:1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28832372
- Penna F, Baccino FM, Costelli P. Coming back: autophagy in cachexia. Curr Opin Clin Nutr Metab Care. [Internet]. 2014;17:241–246. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24535215
- Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. [Internet]. 2011 [cited 2014 Jul 15];12:489–495. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21296615
- Prado CM, Sawyer MB, Ghosh S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr. [Internet]. 2013 cited 2017 Nov 3;98:1012–1019. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23966429
- Theilen NT, Kunkel GH, Tyagi SC. The role of exercise and TFAM in preventing skeletal muscle atrophy. J Cell Physiol. [Internet]. 2017 [cited 2018 Jun 30];232:2348–2358. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27966783
- Li JP, Lu L, Wang LJ, et al. Increased serum levels of S100B are related to the severity of cardiac dysfunction, renal insufficiency and major cardiac events in patients with chronic heart failure. Clin Biochem. [Internet]. 2011 [cited 2015 Sep 25];44:984–988. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21640093
- Niewczas MA, Gohda T, Skupien J, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol. [Internet]. 2012 [cited 2015 Sep 25];23:507–515. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3294310&tool=pmcentrez&rendertype=abstract
- Seruga B, Zhang H, Bernstein LJ, et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008 [cited 2015 Jul 22];8:887–899. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18846100
- Walston J, Fedarko N, Yang H, et al. The physical and biological characterization of a frail mouse model. J Gerontol A Biol Sci Med Sci. [Internet]. 2008 [cited 2015 Sep 25];63:391–398. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18426963
- Cai D, Frantz JD, Tawa NE, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. [Internet]. 2004 [cited 2015 Jun 12];119:285–298. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15479644
- Bonetto A, Aydogdu T, Kunzevitzky N, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. [Internet]. 2011 [cited 2015 Sep 25];6:e22538. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3140523&tool=pmcentrez&rendertype=abstract
- Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr. [Internet]. 2014 [cited 2015 Feb 10];33:737–748. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24785098
- Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. [Internet]. 1997 [cited 2015 Aug 18];30:1758–1764. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9385904
- Sartori R, Schirwis E, Blaauw B, et al. BMP signaling controls muscle mass. Nat Genet. [Internet]. 2013 [cited 2015 Sep 2];45:1309–1318. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24076600
- Penna F, Costamagna D, Fanzani A, et al. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One. 2010;5(10):e13604.
- He WA, Berardi E, Cardillo VM, et al. NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest. [Internet]. 2013 [cited 2015 Sep 25];123:4821–4835. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3809785&tool=pmcentrez&rendertype=abstract
- Sousa-Victor P, García-Prat L, Muñoz-Cánoves P. New mechanisms driving muscle stem cell regenerative decline with aging. Int J Dev Biol. [Internet]. 2018 [cited 2018 Jun 30];62:583–590. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29938769
- Muscaritoli M, Molfino A, Lucia S, et al. Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach. Crit Rev Oncol Hematol. [Internet]. 2015 [cited 2015 Sep 25];94:251–259. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25468676
- Aoyagi T, Terracina KP, Raza A, et al. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. [Internet]. 2015 [cited 2015 Sep 25];7:17–29. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4398892&tool=pmcentrez&rendertype=abstract
- Argilés JM, López-Soriano FJ, Stemmler B, et al. Novel targeted therapies for cancer cachexia. Biochem J. [Internet]. 2017 [cited 2018 Oct 7];474:2663–2678. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28751550
- Chen J, Splenser A, Guillory B, et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. [Internet]. 2015 [cited 2018 Oct 7];6:132–143. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26136189
- Garcia JM. What is next after anamorelin? Curr Opin Support Palliat Care. [Internet]. 2017 [cited 2018 Oct 7];11:266–271. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28957883
- Anderson LJ, Albrecht ED, Garcia JM. Update on management of cancer-related cachexia. Curr Oncol Rep. [Internet]. 2017 [cited 2018 Oct 7];19:3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28138933
- Katakami N, Uchino J, Yokoyama T, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. [Internet]. 2018 [cited 2018 Oct 7];124:606–616. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29205286
- Talbert EE, Yang J, Mace TA, et al. Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities. Mol Cancer Ther. [Internet]. 2017 [cited 2017 Jul 24];16:344–356. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27811010
- Prado CMM, Bekaii-Saab T, Doyle LA, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer. [Internet]. 2012 [cited 2015 Sep 25];106:1583–1586. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3349178&tool=pmcentrez&rendertype=abstract
- Penna F, Bonetto A, Aversa Z, et al. Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J Cachexia Sarcopenia Muscle. [Internet]. 2016 [cited 2016 Dec 20];7:345–354. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27239411
- Pin F, Minero VG, Penna F, et al. Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia. Front Physiol. [Internet]. 2017 [cited 2017 Nov 3];8:213. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28469577
- Sincennes M-C, Brun CE, Rudnicki MA. Concise review: epigenetic regulation of myogenesis in health and disease. Stem Cells Transl Med. [Internet]. 2016 [cited 2018 Jun 30];5:282–290. Available from: http://doi.wiley.com/10.5966/sctm.2015-0266
- Ganguly S, Seth S. A translational perspective on histone acetylation modulators in psychiatric disorders. Psychopharmacol (Berl). [Internet]. 2018 [cited 2018 Jun 30];235:1867–1873. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29915963
- Walsh ME, Van Remmen H. Emerging roles for histone deacetylases in age-related muscle atrophy. Nutr Heal Aging. [Internet]. 2016 [cited 2018 Jun 30];4:17–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28035339
- Singh A, Bishayee A, Pandey A. Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy. Nutrients. [Internet]. 2018 [cited 2018 Jun 30];10:731. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29882797
- Naia L, Rego AC. Sirtuins: double players in Huntington’s disease. Biochim Biophys Acta. [Internet]. 2015 [cited 2015 Sep 26];1852:2183–2194. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26163995
- Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. [Internet]. 2010 [cited 2015 Aug 4];5:253–295. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2866163&tool=pmcentrez&rendertype=abstract
- Yanginlar C, Logie C. HDAC11 is a regulator of diverse immune functions. Biochim Biophys Acta - Gene Regul Mech. [Internet]. 2018 [cited 2018 Jun 30];1861:54–59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29222071
- Beharry AW, Judge AR. Differential expression of HDAC and HAT genes in atrophying skeletal muscle. Muscle Nerve. [Internet]. 2015 [cited 2018 Jun 30];52:1098–1101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26372908
- Bongers KS, Fox DK, Ebert SM, et al. Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4. Am J Physiol Metab. [Internet]. 2013 [cited 2018 Jun 30];305:E907–E915. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23941879
- Moresi V, Williams AH, Meadows E, et al. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell. [Internet]. 2010 [cited 2018 Jun 30];143:35–45. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0092867410010147
- Ratti F, Ramond F, Moncollin V, et al. Histone deacetylase 6 is a FoxO transcription factor-dependent effector in skeletal muscle atrophy. J Biol Chem. [Internet]. 2015 [cited 2018 Jun 30];290:4215–4224. Available from: http://www.jbc.org/lookup/doi/10.1074/jbc.M114.600916
- Bertaggia E, Coletto L, Sandri M. Posttranslational modifications control FoxO3 activity during denervation. Am J Physiol Physiol. [Internet]. 2012 [cited 2018 Jun 30];302:C587–C596. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22094330
- Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. [Internet]. 2005 [cited 2018 Jun 30];352:1967–1976. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa041892
- To M, Swallow EB, Akashi K, et al. Reduced HDAC2 in skeletal muscle of COPD patients. Respir Res. [Internet]. 2017 [cited 2018 Jun 30];18:99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28526090
- Cantó C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. [Internet]. 2009 [cited 2015 May 31];20:98–105. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3627054&tool=pmcentrez&rendertype=abstract
- Price NL, Gomes AP, Ling AJY, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. [Internet]. 2012 [cited 2015 Jul 2];15:675–690. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3545644&tool=pmcentrez&rendertype=abstract
- Bordone L, Cohen D, Robinson A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. [Internet]. 2007 [cited 2015 Sep 26];6:759–767. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17877786
- Lee D, Goldberg AL. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J Biol Chem. [Internet]. 2013 [cited 2015 Sep 26];288:30515–30526. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3798522&tool=pmcentrez&rendertype=abstract
- Chalkiadaki A, Guarente L. The multifaceted functions of sirtuins in cancer. Nat Rev Cancer. 2015 [cited 2015 Sep 18];15:608–624. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26383140
- Rokach O, Sekulic-Jablanovic M, Voermans N, et al. Epigenetic changes as a common trigger of muscle weakness in congenital myopathies. Hum Mol Genet. [Internet]. 2015 [cited 2018 Jun 30];24:4636–4647. Available from: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddv195
- Evans L, Ferguson B. Food bioactive HDAC inhibitors in the epigenetic regulation of heart failure. Nutrients. [Internet]. 2018 [cited 2018 Oct 7];10:1120. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30126190
- Hadden MJ, Advani A. Histone deacetylase inhibitors and diabetic kidney disease. Int J Mol Sci. [Internet]. 2018 [cited 2018 Oct 7];19:2630. Available from: http://www.mdpi.com/1422-0067/19/9/2630
- Ziemka-Nalecz M, Jaworska J, Sypecka J, et al. Histone deacetylase inhibitors: a therapeutic key in neurological disorders? J Neuropathol Exp Neurol. [Internet]. 2018 [cited 2018 Oct 7];77:855–870. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30165682
- Bao L, Diao H, Dong N, et al. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation. Cell Biol Toxicol. [Internet]. 2016 [cited 2018 Oct 7];32:469–482. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27423454
- Ansari J, Shackelford RE, El-Osta H. Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res. [Internet]. 2016 [cited 2018 Oct 7];5:155–171. Available from: http://tlcr.amegroups.com/article/view/7437/6834
- Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012 [cited 2018 Oct 7];12:237–251. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22437869
- Ellmeier W, Seiser C. Histone deacetylase function in CD4+ T cells. Nat Rev Immunol. 2018 [cited 2018 Oct 7];18:617–634. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30022149
- Pirruccello-Straub M, Jackson J, Wawersik S, et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci Rep. [Internet]. 2018 [cited 2018 Jun 30];8:2292. Available from: http://www.nature.com/articles/s41598-018-20524-9
- Han D-S, Huang H-P, Wang T-G, et al. Transcription activation of myostatin by trichostatin A in differentiated C2C12 myocytes via ASK1-MKK3/4/6-JNK and p38 mitogen-activated protein kinase pathways. J Cell Biochem. [Internet]. 2010 [cited 2018 Oct 7];111:564–573. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20568119
- Minetti GC, Colussi C, Adami R, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. [Internet]. 2006 [cited 2018 Oct 7];12:1147–1150. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16980968
- Bonetto A, Penna F, Minero VG, et al. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets. [Internet]. 2009 [cited 2016 Dec 20];9:608–616. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19508174
- Lee J, Ko J, Yi JY. Histone deacetylase inhibitor (HDACi) upregulates activin A and activates the Smad signaling pathway in melanomas. J Dermatol Sci. [Internet]. 2018 [cited 2018 Oct 7];90:13–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29290529
- Thissen J-P, Loumaye A, Rôle de l’Activine A, et al. Myostatine dans la cachexie cancéreuse. Ann Endocrinol (Paris). [Internet]. 2013 [cited 2018 Oct 7];74:79–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23566617
- Atlante S, Chegaev K, Cencioni C, et al. Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors. Eur J Med Chem. [Internet]. 2018 [cited 2018 Jun 30];144:612–625. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0223523417310772
- Murray RL, Zhang W, Iwaniuk M, et al. Dietary tributyrin, an HDAC inhibitor, promotes muscle growth through enhanced terminal differentiation of satellite cells. Physiol Rep. [Internet]. 2018 [cited 2018 Jun 30];6:e13706. Available from: http://doi.wiley.com/10.14814/phy2.13706
- Dupré-Aucouturier S, Castells J, Freyssenet D, et al. Trichostatin A, a histone deacetylase inhibitor, modulates unloaded-induced skeletal muscle atrophy. J Appl Physiol. [Internet]. 2015 [cited 2018 Jun 30];119:342–351. Available from: http://www.physiology.org/doi/10.1152/japplphysiol.01031.2014
- Avila AM, Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest. [Internet]. 2007 [cited 2018 Jun 30];117:659–671. Available from: http://www.jci.org/cgi/doi/10.1172/JCI29562
- Lee J, Ryu H, Keum G, et al. Therapeutic targeting of epigenetic components in amyotrophic lateral sclerosis (ALS). Curr Med Chem. [Internet]. 2014 [cited 2018 Jun 30];21:3576–3582. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25005187
- Buonvicino D, Felici R, Ranieri G, et al. Effects of class II-selective histone deacetylase inhibitor on neuromuscular function and disease progression in SOD1-ALS Mice. Neurosci. [Internet]. 2018 [cited 2018 Jun 30];379:228–238. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0306452218302136
- Consalvi S, Mozzetta C, Bettica P, et al. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med. [Internet]. 2013 [cited 2018 Oct 7];19:1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23552722
- Walsh ME, Bhattacharya A, Sataranatarajan K, et al. The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging. Aging Cell. [Internet]. 2015 [cited 2018 Oct 7];14:957–970. Available from: http://doi.wiley.com/10.1111/acel.12387
- Benny Klimek ME, Aydogdu T, Link MJ, et al. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun. [Internet]. 2010 [cited 2018 Jun 30];391:1548–1554. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0006291X09024966
- Sun R, Zhang S, Hu W, et al. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia. Am J Physiol Cell Physiol. [Internet]. 2016 [cited 2018 Jun 30];311:C101–15. Available from: http://www.physiology.org/doi/10.1152/ajpcell.00344.2015
- Tseng Y-C, Kulp SK, Lai I-L, et al. Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia. J Natl Cancer Inst. [Internet]. 2015 [cited 2018 Jun 30];107:djv274. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26464423
- Henderson SE, Ding L-Y, Mo X, et al. Suppression of tumor growth and muscle wasting in a transgenic mouse model of pancreatic cancer by the novel histone deacetylase inhibitor AR-42. Neoplasia. [Internet]. 2016 [cited 2018 Jun 30];18:765–774. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1476558616301725
- Enßle JC, Boedicker C, Wanior M, et al. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. Cancer Lett. [Internet]. 2018 [cited 2018 Jun 30];428:160–172. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0304383518302994
- Hölscher AS, Schulz WA, Pinkerneil M, et al. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. Clin Epigenetics. [Internet]. 2018 [cited 2018 Jun 30];10(1). Available from: https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-017-0434-3
- Segatto M, Fittipaldi R, Pin F, et al. Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival. Nat Commun. 2017;8(1):1707.
- Lim J, Song Y, Jang J-H, et al. Aspirin-inspired acetyl-donating HDACs inhibitors. Arch Pharm Res. [Internet]. 2018 [cited 2018 Jun 30]. Available from: http://link.springer.com/10.1007/s12272-018-1045-z
- Zinna EM, Yarasheski KE. Exercise treatment to counteract protein wasting of chronic diseases. Curr Opin Clin Nutr Metab Care. [Internet]. 2003 [cited 2015 Sep 26];6:87–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12496685
- Penna F, Ballarò R, Beltrá M, et al. Modulating metabolism to improve cancer-induced muscle wasting. Oxid Med Cell Longev. 2018;2018:7153610.
- Gaur V, Connor T, Venardos K, et al. Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice. Diabetes Obes Metab. [Internet]. 2017 [cited 2018 Jun 30];19:936–943. Available from: http://doi.wiley.com/10.1111/dom.12896
- He WA, Calore F, Londhe P, et al. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci USA. [Internet]. 2014 [cited 2016 Jan 4];111:4525–4529. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3970508&tool=pmcentrez&rendertype=abstract
- Zhang G, Liu Z, Ding H, et al. Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat Commun. [Internet]. 2017 [cited 2018 Jun 30];8(589). Available from: http://www.nature.com/articles/s41467-017-00726-x
- Chao OS, Chang TC, Di Bella MA, et al. The HDAC6 inhibitor tubacin induces release of CD133+ extracellular vesicles from cancer cells. J Cell Biochem. [Internet]. 2017 [cited 2018 Jun 30];118:4414–4424. Available from: http://doi.wiley.com/10.1002/jcb.26095
- Pigna E, Renzini A, Greco E, et al. HDAC4 preserves skeletal muscle structure following long-term denervation by mediating distinct cellular responses. SkeletMuscle. [Internet]. 2018 [cited 2018 Jun 30];8:6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29477142